| June 5, 2008 |
| March 26, 2009 |
| April 2007 |
| October 2007 (final data collection date for primary outcome measure) |
- Percentage of Participants Experiencing at Least a 1-Grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
- Percentage of Participants Experiencing at Least a 1-Grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 20 (Post-Treatment) [ Time Frame: Week 20 ] [ Designated as safety issue: No ]
|
| Overall eyelash prominence as measured by the Global Eyelash Assessment (GEA) score [ Time Frame: Month 4 ] [ Designated as safety issue: No ] |
| Complete list of historical versions of study NCT00693420 on ClinicalTrials.gov Archive Site |
- Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
- Upper Eyelash Length as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-Treatment) [ Time Frame: Week 20 ] [ Designated as safety issue: No ]
- Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
- Upper Eyelash Thickness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-Treatment) [ Time Frame: Week 20 ] [ Designated as safety issue: No ]
- Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
- Upper Eyelash Darkness as Measured by Digital Image Analysis in Terms of Change From Baseline to Week 20 (Post-Treatment) [ Time Frame: Week 20 ] [ Designated as safety issue: No ]
|
- Upper eyelash length as measured by image analysis [ Time Frame: Day 1, Week 1, Month 1-5 ] [ Designated as safety issue: No ]
- Upper eyelash thickness as measured by image analysis [ Time Frame: Day 1, Week 1, Month 1-5 ] [ Designated as safety issue: No ]
|
| |
| Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence |
| |
This study evaluates the safety and effectiveness of topical bimatoprost solution for enhancing eyelash prominence. |
| |
| Phase III |
| Interventional |
| Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
| Eyelashes |
- Drug: Bimatoprost 0.03% sterile solution
- Drug: vehicle sterile solution
|
- Experimental: Bimatoprost 0.03% solution
- Placebo Comparator: Vehicle solution
|
| |
| |
| Completed |
| 278 |
| December 2007 |
| October 2007 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Dissatisfaction with eyelash prominence,
- Eyelash prominence assessment of minimal or moderate,
- Ability to provide written informed consent
Exclusion Criteria:
- Subjects without visible lashes,
- Asymmetrical (uneven lashes or longer on one side than the other) eyelashes,
- Any eye disease or abnormality,
- Eye surgery,
- Permanent eyeliner,
- Eyelash implants,
- Eyelash extension application,
- Any use of eyelash growth products within 6 months of study entry,
- Treatments that may effect hair growth,
- Subjects requiring eye drop medications for glaucoma,
- Subjects having a situation or condition, which the study doctor feels might put you at risk, may make the study results confusing, or may interfere with the study.
|
| Both |
| 18 Years and older |
| Yes |
| Contact information is only displayed when the study is recruiting subjects |
| United States, Canada |
| |
| NCT00693420 |
| Therapeutic Area Head, Allergan, Inc. |
| 192024-032 |
| Allergan |
|
| Study Director: |
Medical Director |
Allergan |
|
|
| Allergan |
| March 2009 |
